The list of such microorganisms continues to grow and includes many strains of lactic acid bacilli (eg, Lactobacillus and Bifidobacterium), a nonpathogenic strain of Escherichia coli (eg, E. coli Nissle 1917), Clostridium butyricum, Streptococcus salivarius, and Saccharomyces boulardii (a nonpathogenic strain of yeast).
One such example is the probiotic bacterium Escherichia coli Nissle 1917 (E. coli Nissle, or EcN), a strain that was first isolated in WWI from the stool of a soldier who did not develop
Recently, we have found that hBD-2 induction by probiotic Escherichia coli Nissle 1917 was mediated through NF-kappaB- and AP-1-dependent pathways. The aim of the present study was to identify the responsible bacterial factor. E. coli Nissle 1917 culture supernatant was found to be more potent than the pellet, indicating a soluble or shed factor.
the probiotic Escherichia coli (E. coli), Nissle 1917, to secrete proteins of therapeutic value into its surroundings. When engineered to secrete an antibody that blocks inflammation, this
By metabolic engineering, Escherichia coli Nissle 1917 (EcN) was reprogrammed to synthesize butyrate (referred to as biobutyrate) and designated EcN-BUT. The adopted strategy includes construction
However, recent studies have shown that probiotic Escherichia coli Nissle 1917 (EcN) bacteria can also colonize tumors and may exhibit a better safety proËœle than S. typhimurium 24 .
Escherichia coli Nissle 1917 (EcN) is among the best characterised probiotics, with a proven clinical impact in a range of conditions. Despite this, the mechanisms underlying these "probiotic effects" are not clearly defined. Here we applied random transposon mutagenesis to identify genes relevant to the interaction of EcN with intestinal epithelial cells. This demonstrated mutants disrupted
Escherichia coli Nissle 1917 (EcN) is the active component of Mutaflor® (Ardeypharm GmbH, Herdecke, Germany), a probiotic drug licensed in several countries for the treatment of multiple
Escherichia coli Nissle 1917 (EcN) naturally synthesizes and secrets heparosan as its capsular polysaccharides. In this study, we described the metabolic engineering of EcN to enhance heparosan production by optimizing the biosynthesis of precursors UDP-GlcA and UDP-GlcNAc and the expression of heparosan synthase.
YD8f. isg83qwe4h.pages.dev/798isg83qwe4h.pages.dev/103isg83qwe4h.pages.dev/283isg83qwe4h.pages.dev/596isg83qwe4h.pages.dev/674isg83qwe4h.pages.dev/537isg83qwe4h.pages.dev/492isg83qwe4h.pages.dev/366isg83qwe4h.pages.dev/531isg83qwe4h.pages.dev/28isg83qwe4h.pages.dev/808isg83qwe4h.pages.dev/638isg83qwe4h.pages.dev/796isg83qwe4h.pages.dev/284isg83qwe4h.pages.dev/807
escherichia coli nissle 1917 probiotic
